Cargando…

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer

Immune check point inhibitor (ICI) therapy can be a potentially effective salvage treatment for anaplastic thyroid cancer (ATC) with progression despite standard of care therapies. We report a case of unresectable treatment-naïve ATC showing a dramatic and durable response to first-line pembrolizuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nabhan, Fadi, Kander, Elizabeth, Shen, Rulong, Agrawal, Amit, Sukrithan, Vineeth, Zhou, Ye, Goyal, Ashima, Roll, Katie, Shah, Manisha, Konda, Bhavana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166484/ https://www.ncbi.nlm.nih.gov/pubmed/34123437 http://dx.doi.org/10.1155/2021/5521649

Ejemplares similares

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
por: Sukrithan, Vineeth, et al.
Publicado: (2023)

Kinase inhibitors in thyroid cancers
por: Sukrithan, Vineeth, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Pancreatic Cancer Heralded by Worsening Glycemic Control: A Report of Two Cases
por: Desai, Dimpi, et al.
Publicado: (2017)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

Systemic mastocytosis presenting as cardiac tamponade with CD25(+) pericardial mast cells
por: Sukrithan, Vineeth K., et al.
Publicado: (2016)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer
por: Iwasaki, Hiroyuki, et al.
Publicado: (2023)

MON-530 Local Lymph Node Metastasis Is Less Common in RAS- Mutated Thyroid Cancer Compared to BRAFV600E- Mutated Thyroid Cancer
por: Endo, Mayumi, et al.
Publicado: (2020)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
por: Spalart, Valérie, et al.
Publicado: (2019)

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
por: Boudin, Laurys, et al.
Publicado: (2022)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis
por: Song, Young Shin, et al.
Publicado: (2017)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer
por: Zaballos, Miguel A., et al.
Publicado: (2022)

Targeted BRAF Inhibitor Therapy Induces Remission of Unresectable Ampullary Adenocarcinoma
por: Rego, Rayburn, et al.
Publicado: (2022)

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
por: Dierks, Christine, et al.
Publicado: (2021)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
por: Stack, Anthony, et al.
Publicado: (2019)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer
por: Vodopivec, Danica M, et al.
Publicado: (2022)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
por: Azmat, Umal, et al.
Publicado: (2016)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report
por: Luongo, Cristina, et al.
Publicado: (2021)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China
por: Hu, Tu, et al.
Publicado: (2021)

Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study
por: Chen, Song, et al.
Publicado: (2021)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022)

Targeting the BRAF Signaling Pathway in CD133(pos) Cancer Stem Cells of Anaplastic Thyroid Carcinoma
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2019)

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
por: Yeku, Oladapo, et al.
Publicado: (2020)

Real‐world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all‐case postmarketing surveillance in Japan
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3v02pe81aiapiprnavftnot1dm